| overall survival |
phenotype |
12 |
3 |
OS |
| overdose |
phenotype |
5 |
5 |
ODs, overdose, overdose risk, overdose-related outcomes, overdoses |
| overeating |
phenotype |
3 |
2 |
|
| overweight |
phenotype |
13 |
8 |
BMI 25+, BMI 25-30, BMI ≥25 kg/m2, overweight, overweight groups, overweight individuals |
| oxidative phosphorylation |
phenotype |
4 |
1 |
|
| oxidative stress |
phenotype |
16 |
13 |
oxidative stress |
| OXT |
gene |
3 |
2 |
IN OXT, OXT peptide, intranasal OXT, intranasal oxytocin, neuropeptide OXT, nonapeptide, oxytocin |
| OXTR |
gene |
4 |
4 |
OTR, OXT receptor, OXTR, OXTR gene, oxytocin receptor, oxytocin receptor gene |
| oxycodone |
drug |
4 |
4 |
|
| oxygen |
drug |
7 |
2 |
O2 |
| oxytocin |
drug |
7 |
5 |
OT, OXT, intranasal oxytocin, oxytocin, oxytocin peptide |
| OZALC |
cohort |
3 |
1 |
|
| p16Ink4a |
gene |
2 |
2 |
CDKN2A, p16, p16INK4A |
| P2RY12 |
gene |
4 |
3 |
|
| P300 amplitude |
phenotype |
9 |
9 |
P300, P300 amplitude reduction, P300 amplitude reductions, P300 amplitudes, P300 component, P300 decrement, P300 intercept, P300 measurements, P300 reduction, P300 reductions, P300 wave, P3AR, Reduced P300 amplitude, amplitude reduction, limited changes in the P300 |
| P300 component |
phenotype |
5 |
2 |
ERP P300, P300, P300 wave |
| P300 latency |
phenotype |
2 |
2 |
|
| P300 measures |
phenotype |
15 |
2 |
P300 |
| p38 MAPK |
gene |
2 |
2 |
MAPK14, p38, p38 MAPK pathway |
| P3a amplitude |
phenotype |
6 |
5 |
P3a, amplitude of P3a |
